Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 8Squamous Cell Carcinoma of Head and Neck 6Head and Neck Neoplasms 6Neoplasms, Squamous Cell 3Neoplasm Metastasis 2Colorectal Cancer Metastatic 2Carcinoma, Squamous Cell 2Upper Gingival Squamous Cell Carcinoma 1Rectal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Intestinal Neoplasms 1Deglutition Disorders 1Colonic Neoplasms 1Carcinoma 1Acne Vulgaris 1

Interventions

lutetium Lu 177 dotatate 1copper dotatate CU-64 1Tinzaparin 1Lutetium-177 1Lutetium 1Endoscopy 1Drug Therapy 1Colonoscopy 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Intestinal Neoplasms × Cetuximab × Clear all
NCT01134666 2017-06-09

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

Merck KGaA, Darmstadt, Germany

Terminated
165 enrolled
Gastrointestinal

Intestinal Neoplasms, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡